Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by subaru1on Feb 27, 2024 11:35am
87 Views
Post# 35901495

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Great time for Labs to use German news to their advantage

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Great time for Labs to use German news to their advantageAssuming that the 4 qrt revenue are close to 10 millions which would be good and the next 4 qrt with a 20% increase we would close 2024 with around 66 millions of revenue that would be a double and that could put the price of Labs stock around $0,08 to $0,10 with an eps of $0,01 to $0,02.
Have a look to Indiva they ha eps of $0,01 for the last qrt, they have a float of 186 millions and they trade at $0,08.
Have a good day everyone.
<< Previous
Bullboard Posts
Next >>